Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Artbio Inc.
BioCentury | Nov 19, 2024
Deals
More bispecific deals in China: Aclaris/Biosion, Ouro/Keymed, Avenzo/VelaVigo
BioCentury’s Deals Report also includes GSK’s agreement with Flagship-backed Vesalius in Parkinson’s disease, and more
BioCentury | Jul 23, 2024
Product Development
Lead-212’s leading players
Decisions about manufacturing and distribution could be make-or-break for drug developers producing their own lead-212
BioCentury | Jul 22, 2024
Product Development
Battle of the alphas: lead-212 picks up speed in radiopharma
The ɑ-emitting radioisotope’s rapid decay has logistical drawbacks, but its supply could beat actinium-225’s on scale
BioCentury | May 20, 2024
Deals
Deals Report: J&J acquires Proteologix, Fog-ARTbio to develop radiotherapies
Plus: Erasca strikes two deals for RAS-targeting therapies, AZ plans new ADC manufacturing site, and more
BioCentury | Feb 3, 2024
Finance
Series A companies: the class of 2023
An analysis of the technologies behind last year’s biotech series A raisers finds clusters in mitophagy induction, epigenome editing and delivery vectors
BioCentury | Dec 7, 2023
Finance
Dec. 7 Quick Takes: Radiopharma play ARTbio bolsters team with $90M, Novartis vets
Plus: Regeneron’s bispecific heading to FDA and updates for Vanda, J&J, Merck, Ipsen, Genfit
BioCentury | Dec 1, 2023
Product Development
Radiopharmaceuticals’ multi-dimensional next wave
Target, ligand and radioisotope choices fuel the growing field
BioCentury | Oct 7, 2023
Management Tracks
New CEO for Asceneuron
Plus: Genentech veteran Hegde heads to Kite and more from ARTbio, Takeda, Anebulo and MMRF
BioCentury | Jun 22, 2023
Emerging Company Profile
ARTbio: manufacturing strategy to lead on lead-212 radiotherapies
With $23M seed and tech from alpha-emitter pioneers behind Xofigo, ARTbio to decentralize manufacturing of cancer radiotherapies
Items per page:
1 - 9 of 9